Intravenous immunoglobulins for epilepsy

Intravenous immunoglobulins control scleromyxoedema.

BACKGROUND Scleromyxoedema is a variant of papular mucinosis affecting the skin and internal organs. The different therapeutic approaches proposed for scleromyxoedema are still unsatisfactory. Intravenous immunoglobulin (IVIg) has been successfully employed in the treatment of connective tissue diseases and vasculitides. PATIENTS The successful treatment of three cases of scleromyxoedema with...

Intravenous Immunoglobulins in the Therapy Of

Intravenous immunoglobulin (IVIG) is used for the treatment of numerous immunodeficiency, immune-mediated, and inflammatory disorders in humans. More recently, it has been described for the therapy of immune-mediated hematologic disease in dogs. While the potential benefits of IVIG are tantalizing, and initial reports in dogs are encouraging, there is a marked paucity of controlled studies in t...

Autoimmune neuropathies and treatment with intravenous immunoglobulins

Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

On February 23, 1994, a U.S. Food and Drug Administration (FDA)-licensed immunoglobulin intravenous (IGIV) manufacturer initiated a worldwide withdrawal of two products following an accumulation of 14 reported cases of hepatitis in American and European patients receiving one of these products. By July 1994, this number had grown to 112 in the United States alone (5). A newly licensed version o...

Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins

Alzheimer's disease (AD) is the most common neurodegenerative disorder. Currently available therapies are symptomatic but do not alter underlying disease progression. Immunotherapeutic approaches such as anti Aβ peptide active vaccination trials have had limited success to date. Intravenous immunoblobulin (IVIg) is widely used in immune-mediated neurological disorders such myasthenia gravis and...